

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	Dr Hal Barron					
b)	Position/status	Non-Executive Director					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044					
b)	Nature of the transaction	Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>47.1800</td><td>2,732.837</td></tr></table>		Price(s)	Volume(s)	47.1800	2,732.837
Price(s)	Volume(s)						
47.1800	2,732.837						
d)	Aggregated information Aggregated volume Price	N/A (single transaction)					
e)	Date of the transaction	2025-11-14					
f)	Place of the transaction	New York Stock Exchange (XNYS)					

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc

b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044				
b)	Nature of the transaction	Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>47.1800</td><td>69</td></tr></table>	Price(s)	Volume(s)	47.1800	69
Price(s)	Volume(s)					
47.1800	69					
d)	Aggregated information Aggregated volume Price	N/A (single transaction)				
e)	Date of the transaction	2025-11-14				
f)	Place of the transaction	New York Stock Exchange (XNYS)				

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044	
b)	Nature of the transaction	Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends	
c)	Price(s) and volume(s)	Price(s) 47.1800	Volume(s) 50.851
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-11-14	

f)	Place of the transaction	New York Stock Exchange (XNYS)
----	--------------------------	--------------------------------

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:
No. 3888792

Registered Office:
79 New Oxford Street
London
WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFFSFIAEISEFF